Tuesday, October 27, 2020 3:08:40 PM
Amber Tong
Editor
When the FDA slapped a rejection on Kala Pharma’s dry eye drug last August, the biotech’s execs promised investors that a third Phase III study — they had already started at that point — would reverse their fortune.
Today they made good on that promise, clinching an approval for Eysuvis, an ocular corticosteroid being positioned as a first-line, short term treatment of dry eye disease.
Boasting a technology invented by Bob Langer out of MIT, Eysuvis is a corticosteroid, loteprednol etabonate, delivered by mucus-penetrating particles. It promises to enhance penetration into target tissue on the ocular surface, achieving an effect quicker than systemic corticosteroids and stronger than over-the-counter eye drops.
Kala, with $159.1 million in cash, cash equivalents and short-term investments that it expects to last until Q3 of 2022, expects to launch the drug by year’s end pending some final touches on the salesforce (125 reps to start with) and manufacturing.
The top team, led by CEO Mark Iwicki, has repeatedly emphasized that the market is huge yet untapped, with just a few prescription drugs available in the category. One of them, Shire’s Xiidra, was bought by Novartis for $3.4 billion upfront.
Over 30 million people in the United States live with dry eye disease, of which over 17 million have already been diagnosed by an eye care professional.
Our market research suggests that 80% to 90% of these patients suffer from episodic flares rather than continuous symptoms, and feedback from eye care professionals suggest that these flares are – will be under-managed by current therapies.
In a note from September, Jefferies analyst Biren Amin wrote that steroids are commonly prescribed off-label for flares but risks of elevated intraocular pressure discourage non-corneal specialists from doing so.
Data from STRIDE3, the final Phase III study that finally satisfied regulators, suggested that Eysuvis induced a statistically significant improvement in ocular discomfort severity over placebo.
Doctors Amin spoke to “see the opportunity for it to be adopted by corneal specialists and should remove the barrier for non-corneal specialists to prescribe a steroid type treatment for DED flares.”
AUTHOR
Amber Tong
Editor
amber@endpointsnews.com
@AmberTongPW
Amber Tong on LinkedIn
https://endpts.com/once-rejected-kalas-dry-eye-drug-now-gains-entry-to-a-field-where-novartis-is-grooming-its-own-blockbuster/
Recent KALA News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/06/2024 08:06:16 PM
- KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference • GlobeNewswire Inc. • 08/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 12:02:06 PM
- KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/06/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/01/2024 04:15:09 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/31/2024 08:08:20 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/25/2024 08:10:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/17/2024 09:22:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/16/2024 09:34:43 PM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 07/09/2024 12:54:55 AM
- KALA BIO Announces $12,500,000 Private Placement • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 12:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 12:00:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 12:00:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 12:00:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 12:00:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 12:00:12 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/30/2024 08:03:12 PM
- KALA BIO to Present at Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:08:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:06:15 PM
- KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/14/2024 08:05:00 PM
- KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:30:19 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM